2012 News Releases

2012 News Releases

Phase II Study Indicates that Fibrinogen Concentrate Given as a First-Line Therapy Safely Reduces Need for Transfusion after Aortic Surgery
19 Dec 2012

Clinical study results published today in the journal Anesthesiology showed that human fibrinogen concentrate can significantly reduce the need for blood transfusion when given as an intra-operative, targeted first-line hemostatic therapy in bleeding patients undergoing aortic replacement surgery.

CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a “ChamPIon”
13 Dec 2012

CSL Behring has teamed up with Professional Supercross racer Carl Schlacht to launch www.IamaChamPIon.com. This new online resource is part of the I am a ChamPIon campaign, a partnership that aims to raise awareness of primary immunodeficiency disease (PI or PIDD) while encouraging those with the condition to pursue their dreams despite the challenges that PI can pose.

CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
03 Dec 2012

CSL Behring’s parent company, CSL Limited (ASX:CSL), reaffirms the company’s commitment to responsible business practice and sustainable development in its fourth Corporate Responsibility Report – Our Corporate Responsibility 2012. The report details CSL’s performance across key corporate responsibility priority areas for the period July 1, 2011 through June 30, 2012.

Study Supports Efficacy, Safety of Hizentra® in Japanese Patients with Primary Immunodeficiency Disease
04 Oct 2012

A new study conducted in Japan supports the previously demonstrated safety and efficacy of Hizentra® (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID). The data were presented today at the 15th Biennial Meeting of the European Society for Immunodeficiencies (ESID).

New Model Compares Economic Value of Subcutaneous Immunoglobulin Therapy with Intravenous Immunoglobulin
04 Oct 2012

Analysis using a new economic model demonstrates that higher dosing of subcutaneous immunoglobulin therapy (SCIg) is a cost-effective alternative to intravenous IgG replacement therapy (IVIG) in patients with primary immunodeficiencies (PID).

Avery-Landsteiner Prize for Immunology Awarded to Alain Fischer of Paris, France, by German Society for Immunology
07 Sep 2012

The German Society for Immunology (DGfI) has awarded its 2012 Avery-Landsteiner Prize to Alain Fischer, M.D., Ph.D., of Paris, France, for his milestone discoveries and treatment developments in the management of hereditary immunodeficiencies. The Prize was presented at the European Congress for Immunology in Glasgow, Scotland today.